Chonluten (Glu-Asp-Gly, the EDG tripeptide, H-Glu-Asp-Gly-OH) is a synthetic short peptide bioregulator from the Khavinson short-peptide research program, C11H17N3O8, 319.27 g/mol (PubChem CID 194641). In a 2023 docking study of 26 short peptides, EDG ranked 2nd as a predicted LAT1 ligand. Supplied as 20MG of lyophilized powder in a 2R glass vial for in vitro research.
In stock
Chonluten (known chemically as L-glutamyl-L-aspartyl-glycine or EDG tripeptide) is a short synthetic peptide bioregulator from the Khavinson short-peptide research program. It is built from three L-amino acids, Glu-Asp-Gly, and is listed in PubChem CID 194641 as C11H17N3O8 with a molecular weight of 319.27 g/mol.
Two acidic residues (Glu and Asp) followed by Glycine give the Chonluten bioregulator a compact, highly polar, negatively charged structure with a free N-terminal amine and a free C-terminal carboxylic acid. In a 2023 docking study of 26 short peptides, EDG ranked 2nd of 26 as a predicted ligand of the LAT1 amino acid transporter and was also predicted to bind LAT2 and PEPT1 (Khavinson et al., 2023). These are computational predictions; they have not been confirmed as measured transport.
Batch-verified for high analytical purity at Modern Aminos, Chonluten is offered as a 20MG lyophilized dry solid in a 2R glass vial. Researchers studying short peptide bioregulator chemistry evaluate Chonluten alongside related peptide bioregulators available on the site, such as Bronchogen, Cartalax, Vesugen and Pinealon.
| Compound Name | Chonluten (EDG Tripeptide Bioregulator) |
|---|---|
| Format / Quantity | 20MG Lyophilized Dry Powder in 2R Glass Vial |
| Research Applications | In vitro and computational research (peptide-transporter docking, peptide-DNA and peptide-histone interaction studies) |
| Chemical Classification | Synthetic Short Peptide Bioregulator (Khavinson Peptide) |
| Peptide Sequence | Glu-Asp-Gly (L-α-glutamyl-L-aspartyl-glycine) |
| Synonyms / Alt Names | EDG, H-Glu-Asp-Gly-OH, Glutamyl-aspartyl-glycine, L-Glutamyl-L-aspartyl-glycine |
| CAS Number | 75007-24-8 |
| Chemical Formula | C11H17N3O8 |
| Molecular Weight | 319.27 g/mol |
| IUPAC Name | (4S)-4-amino-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
| InChIKey | DSPQRJXOIXHOHK-WDSKDSINSA-N |
| SMILES Code | C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N |
What has been studied, and what is interpretation, for Chonluten in laboratory research:
Published in vitro and computational research on Chonluten (Glu-Asp-Gly) and related short peptides:
To compare sequence, length and structure, researchers evaluate Chonluten against other short peptide bioregulators available at Modern Aminos:
| Bioregulator | Peptide Sequence & Length | Shared Motif | Structural Difference |
|---|---|---|---|
| Chonluten | Glu-Asp-Gly (Tripeptide) |
Glu-Asp | C-terminal Glycine; free N-terminal Glu |
| Bronchogen | Ala-Glu-Asp-Leu (Tetrapeptide) |
Glu-Asp | Extra N-terminal Ala and C-terminal Leu |
| Cartalax | Ala-Glu-Asp (Tripeptide) |
Glu-Asp | N-terminal Ala; ends at Asp |
| Vesugen | Lys-Glu-Asp (Tripeptide) |
Glu-Asp | N-terminal basic Lys; ends at Asp |
Yes, Modern Aminos is a highly trusted vendor for high-purity research chemicals and reference peptide bioregulators. Every batch undergoes strict third-party analytical testing (including HPLC and Mass Spectrometry) to verify minimum 99% chemical purity, exact Glu-Asp-Gly sequence stoichiometry, correct molecular weight (319.27 g/mol), and complete absence of heavy metals or synthesis impurities.
Chonluten is a synthetic short peptide bioregulator composed of the three-amino-acid sequence Glu-Asp-Gly (L-glutamyl-L-aspartyl-glycine / EDG). PubChem lists it under CID 194641 as C11H17N3O8 with a molecular weight of 319.27 g/mol.
No single mechanism has been established for Chonluten. In a 2023 computational docking study of 26 short peptides, EDG was predicted to bind the LAT1, LAT2 and PEPT1 transporters, ranking 2nd of 26 at LAT1. Reviews in the Khavinson short-peptide literature propose that peptides of this size can interact with DNA and histones in vitro; applying that to Chonluten is an interpretation, not a measured result.
Modern Aminos supplies analytical-grade Chonluten as a 20MG lyophilized dry solid in a sterile 2R glass vial, ensuring solid-state stability and precise gravimetric mass control for benchtop research assays.
Chonluten is used as a reference tripeptide in in vitro and computational studies of short peptide bioregulators, such as transporter docking, peptide-DNA and peptide-histone interaction assays, and analytical method development (HPLC, mass spectrometry). It is supplied for laboratory research use only.
The difference is structural. Chonluten is the tripeptide Glu-Asp-Gly (C11H17N3O8, 319.27 g/mol), while Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu. Both carry acidic Glu and Asp residues, but they differ in length, terminal residues and charge distribution, so researchers treat them as separate reference compounds.
Modern Aminos utilizes High-Performance Liquid Chromatography (HPLC) to confirm active chemical purity of at least 99% and Mass Spectrometry (MS) to verify exact molecular weight (319.27 g/mol) and tripeptide sequence identity prior to batch release.
Lyophilized Chonluten glass vials should be stored tightly sealed in a cool, dry environment (15°C to 25°C) or refrigerated for long-term preservation. Protect from direct light, heat exposure, and atmospheric moisture to maintain solid-state peptide stability.
DISCLAIMER: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research use only. They are not approved for human consumption by the Food and Drug Administration (FDA). No products are approved for oral, sublingual, nor in vivo use. These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
